SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced that the first patient has been dosed in the Part B dose-expansion portion of the Phase 1/2 ASTRA clinical trial of SB-007, a dual adeno-associated viral (AAV) vector gene therapy for the treatment of Stargardt disease.
SpliceBio Appoints Don Munoz as Chief Financial Officer
SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced the appointment of Don Munoz as Chief Financial Officer. Mr. Munoz, who is based in Boston, is a seasoned biotechnology finance leader with deep experience in financial strategy, operations and corporate development, complemented by a strong background in healthcare investment banking.
